<DOC>
	<DOC>NCT02784717</DOC>
	<brief_summary>This non-interventional field study will investigate rivaroxaban under clinical practice conditions for stroke prevention and for prevention of non-CNS systemic embolism in patients with non-valvular atrial fibrillation in China.</brief_summary>
	<brief_title>Xarelto on Prevention of Stroke and Non-central Nervous System Systemic Embolism in Patients With Non-valvular Atrial Fibrillation in China: A Non-interventional Study</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Female and male patients â‰¥ 18 years of age diagnosed with nonvalvular atrial fibrillation Patients for whom the decision to initiate treatment with rivaroxaban to prevent stroke or nonCNS systemic embolism was made as per investigator's routine treatment practice</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>rivaroxaban,</keyword>
	<keyword>non-interventional,</keyword>
	<keyword>atrial fibrillation,</keyword>
	<keyword>stroke prevention,</keyword>
</DOC>